“ALS reversals”: demographics, disease characteristics, treatments, and co-morbidities

Daniel HarrisonSchool of Medicine, Duke University, Durham, NC, USA, Correspondence[email protected]

Paul MehtaAgency for Toxic Substances and Disease Registry, National ALS Registry, Atlanta, GA, USA,

Michael A. van EsDepartment of Neurology, University Medical Center Utrecht, Utrecht, The Netherlands,

Elijah StommelDepartment of Neurology, Geisel School of Medicine at Dartmouth, Hanover, NH, USA,

Vivian E. DroryDepartment of Neurology, Tel-Aviv Medical Center, Tel-Aviv, Israel, and

Beatrice NefussyDepartment of Neurology, Tel-Aviv Medical Center, Tel-Aviv, Israel, and

Leonard H. van den BergDepartment of Neurology, University Medical Center Utrecht, Utrecht, The Netherlands,

Jesse CrayleSchool of Medicine, Duke University, Durham, NC, USA,

Richard BedlackDepartment of Neurology, Duke University and Durham VA Medical Center, Durham, NC, USA

Your download is now in progress and you may close this window